Last reviewed · How we verify

NCT04986267

The Effects of Hormonal Contraceptives on Incidence of ACL Injury Within Menstrual Cycle Phases

Completed Last updated 18 June 2024
What this trial tests

trial testing ACL Rupture in Anterior Cruciate Ligament Rupture in 98 participants. Completed in 31 May 2024.

Timeline
31 May 2021
Primary endpoint
31 May 2024
31 May 2024

Quick facts

Lead sponsorUniversity of South Australia
StatusCompleted
Study typeOBSERVATIONAL
Enrollment98
Start date31 May 2021
Primary completion31 May 2024
Estimated completion31 May 2024
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

University of South Australia

Who can join

Adults 18 to 40, female only, with Anterior Cruciate Ligament Rupture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate how hormonal contraceptives affect ACL rupture incidence within menstrual cycle phases. It is thought hormones such as estrogen and progesterone (which fluctuate throughout the normal menstrual cycle) play a role in the laxity of ligaments within the body. It is hypothesised that around the time of ovulation the ACL undergoes increased laxity, leaving it more likely to be injured. This study will look at the phase of the menstrual cycle in which the ACL injuries occur and whether there are differences due to the use and type of hormonal contraception participants may be using (such as Combined oral contraceptive, Mirena, Implanon), which can modify the levels of circulating estrogen and progesterone. This study involves participants completing an anonymous electronic survey after presenting to a sports or orthopaedic clinic with an ACL rupture. The survey collects information about participant's current ACL injury and any previous knee injuries; typical menstrual cycle patterns and the use of hormonal contraception; and history of sports participation. Responses will be analysed to look for similarities and differences in ACL injury occurrence by menstrual cycle phase and hormonal contraceptive use. The study hypotheses are: 1. Hormonal contraceptives that are known to reduce ovulatory rises in estrogen will have the most consistent pattern of ACL rupture incidence across all phases of the menstrual cycle. 2. There will be a mitigated risk of ACL rupture in the preovulatory phase of the menstrual cycle, relative to the other phases, in women using hormonal contraception compared to those not using hormonal contraception 3. There will be a higher proportion of ACL ruptures during the preovulatory phase of the menstrual cycle in non-hormonal contraceptive users.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Rupture

Currently open trials in the same condition.

Other University of South Australia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04986267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing